Adam Rubinstein, MD
Internal Medicine · Libertyville, ILNPI 1871541839
Payments from drug & device makers
Across 82 payments — averaging $845.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$41K
- Indivior Deutschland GmbH$12K
- Pear Therapeutics (US), Inc.$9K
- MDD US Operations, LLC$7K
- Braeburn Inc.$40
- AstraZeneca$18
- plus $14 from 1 others
What the payments were for
- Consulting fees$25,24636%
- Speaking & faculty fees$33,71949%
- Travel & lodging$8,89913%
- Food & beverage$1,4782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 54 | $40,899 |
| Indivior Deutschland GmbH | 2 | $11,922 |
| Pear Therapeutics (US), Inc. | 9 | $9,419 |
| MDD US Operations, LLC | 13 | $7,030 |
| Braeburn Inc. | 2 | $40 |
| AstraZeneca | 1 | $18 |
| Polynovo North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUBLOCADE$40,750
- Lucemyra/Lofexidine$6,155
- RESET-O$2,450
How this compares
$69,342 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 29 | $2,177 |
| Fentanyl | 13 | $1,839 |
| Rivastigmine | 17 | $1,070 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 42 | $1,058 |
| Atorvastatin Calcium | 104 | $708 |
| Ipratropium Bromide | 36 | $672 |
| Tamsulosin Hcl | 26 | $626 |
| Gabapentin | 37 | $602 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $511 |
| Levothyroxine Sodium | 55 | $496 |
| Oxycodone Hcl | 13 | $488 |
| Prednisone | 24 | $454 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 13 | $445 |
| Losartan Potassium | 40 | $415 |
| Alprazolam | 62 | $414 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Libertyville
- David ReckerLibertyville$868K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.